Metabolic
Tesamorelin
Egrifta · GHRH · analog
A GHRH analog approved abroad (as Egrifta) specifically for HIV-associated abdominal fat — not licensed for general fat loss, and not available via routine UK prescription.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
Tesamorelin is a growth-hormone-releasing hormone analog with a genuinely narrow, specific approval in some countries (branded Egrifta) for reducing excess abdominal fat in people with HIV-associated lipodystrophy — a distinct medical condition, not general 'belly fat'.
Its use for general fat loss or aesthetic purposes is off-label everywhere, and it does not have a routine UK licence or prescription pathway, so what's used for that purpose here is sourced outside standard medicines regulation.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Reduces abdominal fat in HIV-associated lipodystrophy”
Its specific, narrow approved indication, backed by real clinical trials for that condition.
Claim-level citation mapping is in progress.
“Reduces general 'belly fat' in the wider population”
Extrapolated from a specific-condition trial population — not the same claim, and not separately proven.
Claim-level citation mapping is in progress.
“A routine, easily prescribed UK weight-loss option”
It is not routinely available on UK prescription for this use at all.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Approved abroad only for a specific medical condition (HIV-associated lipodystrophy); not routinely available on UK prescription. UK-sourced product for general fat-loss use is unlicensed.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
Discussed by a mix of people interested in its specific approved use and a larger group interested in the general fat-targeting claim, which the site is careful to separate.
Where they’re talking
- r/PeptidesGeneral fat-loss framing dominates community discussion.
- Medical forumsSpecific HIV-lipodystrophy indication is discussed separately.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency